ABCD2 Is a Direct Target of β-Catenin and TCF-4: Implications for X-Linked Adrenoleukodystrophy Therapy

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Park, Chul Yong ^a   Kim, Han Soo ^a   Jang, Jiho ^a   Lee, Hyunji ^a   Lee, Jae Souk ^a   Yoo, Jeong Eun ^a   Lee, Dongjin R ^a   Kim, Dong Wook ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER SUBFAMILY D MEMBER 2 PROTEIN; BETA CATENIN; T CELL FACTOR PROTEIN; T CELL FACTOR PROTEIN 4; UNCLASSIFIED DRUG; VERY LONG CHAIN FATTY ACID;

ABC TRANSPORTER SUBFAMILY D MEMBER 2 GENE; ADRENOLEUKODYSTROPHY; ARTICLE; CANCER CELL CULTURE; CHILDHOOD ADRENOLEUKODYSTROPHY; CHROMATIN IMMUNOPRECIPITATION; COMPUTER MODEL; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; REAL TIME POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS;

ADRENOLEUKODYSTROPHY; ATP-BINDING CASSETTE TRANSPORTERS; BASE SEQUENCE; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; BINDING SITES; FATTY ACIDS; FIBROBLASTS; GENE SILENCING; GREEN FLUORESCENT PROTEINS; HEP G2 CELLS; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; PROMOTER REGIONS, GENETIC; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; UP-REGULATION;

EID: 84874325516     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056242     Document Type: Article

References (45)

1. Mosser J, Douar AM, Sarde CO, Kioschis P, Feil R, et al. (1993) Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361: 726-730.
2. Kemp S, Pujol A, Waterham HR, van Geel BM, Boehm CD, et al. (2001) ABCD1 mutations and the X-linked adrenoleukodystrophy mutation database: role in diagnosis and clinical correlations. Hum Mutat 18: 499-515.
3. Moser HW, Mahmood A, Raymond GV, (2007) X-linked adrenoleukodystrophy. Nat Clin Pract Neurol 3: 140-151.
4. Singh I, Pujol A, (2010) Pathomechanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol 20: 838-844.
5. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, et al. (2009) Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
6. van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, et al. (2008) The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J 22: 4201-4208.
7. Kemp S, Wanders R, (2010) Biochemical aspects of X-linked adrenoleukodystrophy. Brain Pathol 20: 831-837.
8. Jang J, Kang HC, Kim HS, Kim JY, Huh YJ, et al. (2011) Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann Neurol 70: 402-409.
9. Holzinger A, Kammerer S, Berger J, Roscher AA, (1997) cDNA cloning and mRNA expression of the human adrenoleukodystrophy related protein (ALDRP), a peroxisomal ABC transporter. Biochem Biophys Res Commun 239: 261-264.
10. Kemp S, Wei HM, Lu JF, Braiterman LT, McGuinness MC, et al. (1998) Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nat Med 4: 1261-1268.
11. Flavigny E, Sanhaj A, Aubourg P, Cartier N, (1999) Retroviral-mediated adrenoleukodystrophy-related gene transfer corrects very long chain fatty acid metabolism in adrenoleukodystrophy fibroblasts: implications for therapy. FEBS Lett 448: 261-264.
12. Netik A, Forss-Petter S, Holzinger A, Molzer B, Unterrainer G, et al. (1999) Adrenoleukodystrophy-related protein can compensate functionally for adrenoleukodystrophy protein deficiency (X-ALD): implications for therapy. Hum Mol Genet 8: 907-913.
13. Pujol A, Ferrer I, Camps C, Metzger E, Hindelang C, et al. (2004) Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet 13: 2997-3006.
14. Singh I, Pahan K, Khan M, (1998) Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X- adrenoleukodystrophy. FEBS Lett 426: 342-346.
15. Singh J, Khan M, Singh I, (2011) HDAC inhibitor SAHA normalizes the levels of VLCFAs in human skin fibroblasts from X-ALD patients and downregulates the expression of proinflammatory cytokines in Abcd1/2-silenced mouse astrocytes. J Lipid Res 52: 2056-2069.
16. Morita M, Shimozawa N, Kashiwayama Y, Suzuki Y, Imanaka T, (2011) ABC subfamily D proteins and very long chain fatty acid metabolism as novel targets in adrenoleukodystrophy. Curr Drug Targets 12: 694-706.
17. Moon RT, Bowerman B, Boutros M, Perrimon N, (2002) The promise and perils of Wnt signaling through beta-catenin. Science 296: 1644-1646.
18. Lee HY, Kleber M, Hari L, Brault V, Suter U, et al. (2004) Instructive role of Wnt/beta-catenin in sensory fate specification in neural crest stem cells. Science 303: 1020-1023.
19. Nusse R, (2005) Wnt signaling in disease and in development. Cell Res 15: 28-32.
20. Malhotra S, Kincade PW, (2009) Wnt-related molecules and signaling pathway equilibrium in hematopoiesis. Cell Stem Cell 4: 27-36.
21. Moon RT, Kohn AD, De Ferrari GV, Kaykas A, (2004) WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 5: 691-701.
22. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
23. Cadigan KM, Peifer M, (2009) Wnt signaling from development to disease: insights from model systems. Cold Spring Harb Perspect Biol 1: a002881.
24. Arce L, Yokoyama NN, Waterman ML, (2006) Diversity of LEF/TCF action in development and disease. Oncogene 25: 7492-7504.
25. Weinhofer I, Forss-Petter S, Zigman M, Berger J, (2002) Cholesterol regulates ABCD2 expression: implications for the therapy of X-linked adrenoleukodystrophy. Hum Mol Genet 11: 2701-2708.
26. Weinhofer I, Kunze M, Rampler H, Bookout AL, Forss-Petter S, et al. (2005) Liver X receptor alpha interferes with SREBP1c-mediated Abcd2 expression. Novel cross-talk in gene regulation. J Biol Chem 280: 41243-41251.
27. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, et al. (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787.
28. Fuerer C, Nusse R, (2010) Lentiviral vectors to probe and manipulate the Wnt signaling pathway. PLoS One 5: e9370.
29. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR, (1989) Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene 77: 51-59.
30. Pulukuri SM, Gorantla B, Rao JS, (2007) Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 282: 35594-35603.
31. Park CY, Jun HJ, Wakita T, Cheong JH, Hwang SB, (2009) Hepatitis C virus nonstructural 4B protein modulates sterol regulatory element-binding protein signaling via the AKT pathway. J Biol Chem 284: 9237-9246.
32. Paik MJ, Kim KR, Yoon HR, Kim HJ, (2001) Diagnostic patterns of very-long-chain fatty acids in plasma of patients with X-linked adrenoleukodystrophy. J Chromatogr B Biomed Sci Appl 760: 149-157.
33. Moser HW, Moser AB, Kawamura N, Murphy J, Suzuki K, et al. (1980) Adrenoleukodystrophy: elevated C26 fatty acid in cultured skin fibroblasts. Ann Neurol 7: 542-549.
34. de La Coste A, Romagnolo B, Billuart P, Renard CA, Buendia MA, et al. (1998) Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95: 8847-8851.
35. Moser AB, Kreiter N, Bezman L, Lu S, Raymond GV, et al. (1999) Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 45: 100-110.
36. Aubourg P, Adamsbaum C, Lavallard-Rousseau MC, Rocchiccioli F, Cartier N, et al. (1993) A two-year trial of oleic and erucic acids ("Lorenzo's oil") as treatment for adrenomyeloneuropathy. N Engl J Med 329: 745-752.
37. Singh I, Khan M, Key L, Pai S, (1998) Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 339: 702-703.
38. Pai GS, Khan M, Barbosa E, Key LL, Craver JR, et al. (2000) Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 69: 312-322.
39. Engelen M, Ofman R, Dijkgraaf MG, Hijzen M, van der Wardt LA, et al. (2010) Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 362: 276-277.
40. Fourcade S, Savary S, Albet S, Gauthe D, Gondcaille C, et al. (2001) Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha. Eur J Biochem 268: 3490-3500.
41. Gondcaille C, Depreter M, Fourcade S, Lecca MR, Leclercq S, et al. (2005) Phenylbutyrate up-regulates the adrenoleukodystrophy-related gene as a nonclassical peroxisome proliferator. J Cell Biol 169: 93-104.
42. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, et al. (1998) Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
43. Cha MY, Kim CM, Park YM, Ryu WS, (2004) Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 39: 1683-1693.
44. Weinhofer I, Kunze M, Rampler H, Forss-Petter S, Samarut J, et al. (2008) Distinct modulatory roles for thyroid hormone receptors TRalpha and TRbeta in SREBP1-activated ABCD2 expression. Eur J Cell Biol 87: 933-945.
45. Pujol A, Troffer-Charlier N, Metzger E, Chimini G, Mandel JL, (2000) Characterization of the adrenoleukodystrophy-related (ALDR, ABCD2) gene promoter: inductibility by retinoic acid and forskolin. Genomics 70: 131-139.